<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AZOPT - brinzolamide suspension </strong><br>Alcon Laboratories, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use AZOPT® safely and effectively. See full prescribing information for AZOPT®.</span><br><br><span class="Bold">AZOPT® (brinzolamide ophthalmic suspension) 1%</span><br><span class="Bold">Sterile topical ophthalmic drops</span><br><span class="Bold">Initial U.S. Approval: 1998</span>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">AZOPT® is a carbonic anhydrase inhibitor indicated for in the treatment of elevated intraocular pressure in patients with <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> or open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (<span class="Underline"><a href="#splSectionPLRIndicationsUsage">1</a></span>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Instill one drop in the affected eye(s) three times daily (<a href="#splSectionPLRDosageAdministration">2</a>).    </li>
<li>If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten (10) minutes apart (<a href="#splSectionPLRDosageAdministration">2</a>).  </li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Solution containing 10 mg/mL brinzolamide (<span class="Underline"><a href="#splSectionPLRDosageFormsStrength">3</a></span>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>Hypersensitive to any component of this product (<span class="Underline"><a href="#splSectionPLRContraindications">4</a></span>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Sulfonamide <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (<span class="Underline"><a href="#splSection1">5.1</a></span>)  </li>
<li><span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">Corneal edema</span> may occur in patients with low endothelial cell counts (<a href="#splSection2">5.2</a>). </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions are <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and bitter, sour or unusual taste (<span class="Underline"><a href="#splSection6">6.1</a></span>). </p>
<p class="Highlighta">         </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 1-800-757-9195 or FDA at 1-800-FDA-1088 or </span><span class="Bold Underline">www.fda.gov/medwatch</span><span class="Bold">.</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>There is a potential additive effect of the known systemic effects of carbonic anhydrase inhibition in patients receiving both oral and topical carbonic anhydrase inhibitors (<a href="#splSection7">7.1</a>).   </li>
<li>Rare instances of acid-base alterations have occurred with high-dose salicylate therapy (<a href="#splSection8">7.2</a>).  </li>
</ul></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">
1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">
2	DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">
3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">
4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">
5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">
5.1	Sulfonamide <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Corneal Endothelium</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></a></h2>
<h2><a href="#section-5.4" class="toc">
5.4	Acute Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h2><a href="#section-5.5" class="toc">
5.5	Contact Lens Wear</a></h2>
<h1><a href="#section-6" class="toc">
6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">
6.1	Clinical Studies Experience</a></h2>
<h1><a href="#section-7" class="toc">
7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">
7.1	Oral Carbonic Anhydrase Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">
7.2	High-Dose Salicylate Therapy</a></h2>
<h1><a href="#section-8" class="toc">
8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">
8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">
8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">
8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">
8.5	Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">
10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">
11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">
12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">
12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">
12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">
13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">
13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">
14	CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">
16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">
17	PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Sulfonamide Reactions</a></h2>
<h2><a href="#section-15.2" class="toc">
17.2	Temporary <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span></a></h2>
<h2><a href="#section-15.3" class="toc">
17.3	Avoiding Contamination of the Product</a></h2>
<h2><a href="#section-15.4" class="toc">
17.4	Intercurrent Ocular Conditions</a></h2>
<h2><a href="#section-15.5" class="toc">
17.5	Concomitant Topical Ocular Therapy</a></h2>
<h2><a href="#section-15.6" class="toc">
17.6	Contact Lens Wear</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionPLRIndicationsUsage"></a><a name="section-1"></a><p></p>
<h1>
1	INDICATIONS AND USAGE</h1>
<p class="First">AZOPT® (brinzolamide ophthalmic suspension) 1% is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> or open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionPLRDosageAdministration"></a><a name="section-2"></a><p></p>
<h1>
2	DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is 1 drop of AZOPT® (brinzolamide ophthalmic suspension) 1% in the affected eye(s) three times daily. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten (10) minutes apart.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="splSectionPLRDosageFormsStrength"></a><a name="section-3"></a><p></p>
<h1>
3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Solution containing 10 mg/mL brinzolamide.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionPLRContraindications"></a><a name="section-4"></a><p></p>
<h1>
4	CONTRAINDICATIONS</h1>
<p class="First">AZOPT® (brinzolamide ophthalmic suspension) 1% is contraindicated in patients who are hypersensitive to any component of this product.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="splSectionPLRWarnings"></a><a name="section-5"></a><p></p>
<h1>
5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection1"></a><a name="section-5.1"></a><p></p>
<h2>
5.1	Sulfonamide <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">AZOPT® (brinzolamide ophthalmic suspension) 1% is a sulfonamide and although administered topically it is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of AZOPT® (brinzolamide ophthalmic suspension) 1%. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>. Sensitization may recur when a sulfonamide is re-administered irrespective of the route of administration. If signs of serious reactions or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> occur, discontinue the use of this preparation. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Corneal Endothelium</h2>
<p class="First">Carbonic anhydrase activity has been observed in both the cytoplasm and around the plasma membranes of the corneal endothelium. There is an increased potential for developing <span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">corneal edema</span> in patients with low endothelial cell counts. Caution should be used when prescribing AZOPT® (brinzolamide ophthalmic suspension) 1% to this group of patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>
</h2>
<p class="First">AZOPT® (brinzolamide ophthalmic suspension) 1% has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl &lt; 30 mL/min). Because AZOPT® (brinzolamide ophthalmic suspension) 1% and its metabolite are excreted predominantly by the kidney, AZOPT® (brinzolamide ophthalmic suspension) 1% is not recommended in such patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection4"></a><a name="section-5.4"></a><p></p>
<h2>
5.4	Acute Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">The management of patients with acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> requires therapeutic interventions in addition to ocular hypotensive agents. AZOPT® (brinzolamide ophthalmic suspension) 1% has not been studied in patients with acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection5"></a><a name="section-5.5"></a><p></p>
<h2>
5.5	Contact Lens Wear</h2>
<p class="First">The preservative in AZOPT® (brinzolamide ophthalmic suspension) 1%, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation of AZOPT® (brinzolamide ophthalmic suspension) 1%, but may be reinserted 15 minutes after instillation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionPLRAdverseReactions"></a><a name="section-6"></a><p></p>
<h1>
6	ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection6"></a><a name="section-6.1"></a><p></p>
<h2>
6.1	Clinical Studies Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice. <br><br>In clinical studies of AZOPT® (brinzolamide ophthalmic suspension) 1%, the most frequently reported adverse events reported in 5-10% of patients were <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and bitter, sour or unusual taste. Adverse events occurring in 1-5% of patients were <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, foreign body sensation, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4146766" conceptname="Hyperemia">hyperemia</span>, ocular discharge, <span class="product-label-link" type="condition" conceptid="372912" conceptname="Visual discomfort">ocular discomfort</span>, ocular <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span>, ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>. <br><br>The following adverse reactions were reported at an incidence below 1%: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, eye <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="436695" conceptname="Band-shaped keratopathy">keratopathy</span>, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">kidney pain</span>, lid margin crusting or sticky sensation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, tearing and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="splSectionPLRDrugInteract"></a><a name="section-7"></a><p></p>
<h1>
7	DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection7"></a><a name="section-7.1"></a><p></p>
<h2>
7.1	Oral Carbonic Anhydrase Inhibitors</h2>
<p class="First">There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and AZOPT® (brinzolamide ophthalmic suspension) 1%. The concomitant administration of AZOPT® (brinzolamide ophthalmic suspension) 1% and oral carbonic anhydrase inhibitors is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection8"></a><a name="section-7.2"></a><p></p>
<h2>
7.2	High-Dose Salicylate Therapy</h2>
<p class="First">Carbonic anhydrase inhibitors may produce acid-base and electrolyte alterations. These alterations were not reported in the clinical trials with brinzolamide. However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of acid-base alterations have occurred with high-dose salicylate therapy. Therefore, the potential for such drug interactions should be considered in patients receiving AZOPT® (brinzolamide ophthalmic suspension) 1%.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="splSectionPLRPopulations"></a><a name="section-8"></a><p></p>
<h1>
8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPLRPregnancy"></a><a name="section-8.1"></a><p></p>
<h2>
8.1	Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C: </span>Developmental toxicity studies with brinzolamide in rabbits at oral doses of 1, 3, and 6 mg/kg/day (20, 62, and 125 times the recommended human ophthalmic dose) produced maternal toxicity at 6 mg/kg/day and a significant increase in the number of fetal variations, such as accessory skull bones, which was only slightly higher than the historic value at 1 and 6 mg/kg. In rats, statistically decreased body weights of fetuses from dams receiving oral doses of 18 mg/kg/day (375 times the recommended human ophthalmic dose) during gestation were proportional to the reduced maternal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, with no statistically significant effects on organ or tissue development. Increases in unossified sternebrae, reduced ossification of the skull, and unossified hyoid that occurred at 6 and 18 mg/kg were not statistically significant. No treatment-related malformations were seen. Following oral administration of <span class="Sup">14</span>C-brinzolamide to pregnant rats, radioactivity was found to cross the placenta and was present in the fetal tissues and blood. <br><br>There are no adequate and well-controlled studies in pregnant women. AZOPT® (brinzolamide ophthalmic suspension) 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPLRNursing"></a><a name="section-8.2"></a><p></p>
<h2>
8.3	Nursing Mothers</h2>
<p class="First">In a study of brinzolamide in lactating rats, decreases in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in offspring at an oral dose of 15 mg/kg/day (312 times the recommended human ophthalmic dose) were seen during lactation. No other effects were observed. However, following oral administration of <span class="Sup">14</span>C-brinzolamide to lactating rats, radioactivity was found in milk at concentrations below those in the blood and plasma.<br><br>It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from AZOPT® (brinzolamide ophthalmic suspension) 1%, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPLRPediatric"></a><a name="section-8.3"></a><p></p>
<h2>
8.4	Pediatric Use</h2>
<p class="First">A three-month controlled clinical study was conducted in which AZOPT® (brinzolamide ophthalmic suspension) 1% was dosed only twice a day in pediatric patients 4 weeks to 5 years of age. Patients were not required to discontinue their IOP-lowering medication(s) until initiation of monotherapy with AZOPT®. IOP-lowering efficacy was not demonstrated in this study in which the mean decrease in elevated IOP was between 0 and 2 mmHg. Five out of 32 patients demonstrated an increase in corneal diameter of one millimeter.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPLRGeriatric"></a><a name="section-8.4"></a><p></p>
<h2>
8.5	Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionPLROverdose"></a><a name="section-9"></a><p></p>
<h1>
10	OVERDOSAGE</h1>
<p class="First">Although no human data are available, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, development of an acidotic state, and possible nervous system effects may occur following oral administration of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionPLRDescription"></a><a name="section-10"></a><p></p>
<h1>
11	DESCRIPTION</h1>
<p class="First">AZOPT® (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor formulated for multidose topical ophthalmic use. Brinzolamide is described chemically as: (R)-(+)-4-Ethylamino-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno [3,2-e]-1,2-thiazine-6-sulfonamide-1,1- dioxide. Its empirical formula is C<span class="Sub">12</span>H<span class="Sub">21</span>N<span class="Sub">3</span>O<span class="Sub">5</span>S<span class="Sub">3</span>, and its structural formula is: </p>
<div class="Figure"><img alt="
chemical" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e9ea2ae7-1b98-4034-9fba-8ce2225e0145&amp;name=chemical.jpg"></div>
<p>Brinzolamide has a molecular weight of 383.5 and a melting point of about 131°C. It is a white powder, which is insoluble in water, very soluble in methanol and soluble in ethanol.<br><br>AZOPT® (brinzolamide ophthalmic suspension) 1% is supplied as a sterile, aqueous suspension of brinzolamide which has been formulated to be readily suspended and slow settling, following <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>. It has a pH of approximately 7.5 and an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of 300 mOsm/kg.<br><br>Each mL of AZOPT® (brinzolamide ophthalmic suspension) 1% contains: <span class="Bold">Active ingredient: </span>brinzolamide 10 mg. <span class="Bold">Preservative: </span>Benzalkonium chloride 0.1 mg. <span class="Bold">Inactives: </span>mannitol, carbomer 974P, tyloxapol, edetate disodium, sodium chloride, purified water, with hydrochloric acid and/or sodium hydroxide to adjust pH.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionPLRClinicalPharm"></a><a name="section-11"></a><p></p>
<h1>
12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="splSectionPLRMechAction"></a><a name="section-11.1"></a><p></p>
<h2>
12.1	Mechanism of Action</h2>
<p class="First">Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and the <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP).<br><br>AZOPT® (brinzolamide ophthalmic suspension) 1% contains brinzolamide, an inhibitor of carbonic anhydrase II (CA-II). Following topical ocular administration, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> and glaucomatous visual field loss.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="splSectionPLRPharmacokinetics"></a><a name="section-11.2"></a><p></p>
<h2>
12.3	Pharmacokinetics</h2>
<p class="First">Following topical ocular administration, brinzolamide is absorbed into the systemic circulation. Due to its affinity for CA-II, brinzolamide distributes extensively into the RBCs and exhibits a long half-life in whole blood (approximately 111 days). In humans, the metabolite N-desethyl brinzolamide is formed, which also binds to CA and accumulates in RBCs. This metabolite binds mainly to CA-I in the presence of brinzolamide. In plasma, both parent brinzolamide and N-desethyl brinzolamide concentrations are low and generally below assay quantitation limits (&lt;10 ng/mL). Binding to plasma proteins is approximately 60%. Brinzolamide is eliminated predominantly in the urine as unchanged drug. N-Desethyl brinzolamide is also found in the urine along with lower concentrations of the N-desmethoxypropyl and O-desmethyl metabolites.<br><br>An oral pharmacokinetic study was conducted in which healthy volunteers received 1 mg capsules of brinzolamide twice per day for up to 32 weeks. This regimen approximates the amount of drug delivered by topical ocular administration of AZOPT® (brinzolamide ophthalmic suspension) 1% dosed to both eyes three times per day and simulates systemic drug and metabolite concentrations similar to those achieved with long-term topical dosing. RBC CA activity was measured to assess the degree of systemic CA inhibition. Brinzolamide saturation of RBC CA-II was achieved within 4 weeks (RBC concentrations of approximately 20 μM). N-Desethyl brinzolamide accumulated in RBCs to steady-state within 20-28 weeks reaching concentrations ranging from 6-30 μM. The inhibition of CA-II activity at steady-state was approximately 70-75%, which is below the degree of inhibition expected to have a pharmacological effect on renal function or respiration in healthy subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="splSectionPLRNonClinical"></a><a name="section-12"></a><p></p>
<h1>
13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPLRPrecautionsCarcinogen"></a><a name="section-12.1"></a><p></p>
<h2>
13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity data on brinzolamide are not available. The following tests for mutagenic potential were negative: (1) <span class="Italics">in vivo </span>mouse micronucleus assay; (2) <span class="Italics">in vivo </span>sister chromatid exchange assay; and (3) Ames <span class="Italics">E. coli </span>test. The <span class="Italics">in vitro </span>mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> forward mutation assay was negative in the absence of activation, but positive in the presence of microsomal activation. In reproduction studies of brinzolamide in rats, there were no adverse effects on the fertility or reproductive capacity of males or females at doses up to 18 mg/kg/day (375 times the recommended human ophthalmic dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="splSectionPLRClinicalStudies"></a><a name="section-13"></a><p></p>
<h1>
14	CLINICAL STUDIES</h1>
<p class="First">In two, three-month clinical studies, AZOPT® (brinzolamide ophthalmic suspension) 1% dosed three times per day (TID) in patients with elevated intraocular pressure (IOP), produced significant reductions in IOPs (4 -5 mmHg). These IOP reductions are equivalent to the reductions observed with TRUSOPT* (dorzolamide hydrochloride ophthalmic solution) 2% dosed TID in the same studies.<br><br>In two clinical studies in patients with elevated intraocular pressure, AZOPT® (brinzolamide ophthalmic suspension) 1% was associated with less <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> and burning upon instillation than TRUSOPT* 2%.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionPLRHowSupplied"></a><a name="section-14"></a><p></p>
<h1>
16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">AZOPT® (brinzolamide ophthalmic suspension) 1% is supplied in plastic DROP-TAINER® dispensers with a controlled dispensing-tip as follows:<br><br>10 mL NDC 0065-0275-10<br>15 mL NDC 0065-0275-15<br><br><span class="Bold">Storage and Handling<br></span>Store AZOPT® (brinzolamide ophthalmic suspension) 1% at 4-30°C (39-86°F). Shake well before use.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPLRPatientInfo"></a><a name="section-15"></a><p></p>
<h1>
17	PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection9"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Sulfonamide Reactions</h2>
<p class="First">Patients should be advised that if serious or unusual ocular or systemic reactions or signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> occur, they should discontinue the use of the product and consult their physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection10"></a><a name="section-15.2"></a><p></p>
<h2>
17.2	Temporary <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span></h2>
<p class="First">Vision may be temporarily blurred following dosing with AZOPT® (brinzolamide ophthalmic suspension) 1%. Care should be exercised in operating machinery or driving a motor vehicle.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection11"></a><a name="section-15.3"></a><p></p>
<h2>
17.3	Avoiding Contamination of the Product</h2>
<p class="First">Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures or other surfaces, since the product can become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated solutions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection12"></a><a name="section-15.4"></a><p></p>
<h2>
17.4	Intercurrent Ocular Conditions</h2>
<p class="First">Patients should also be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>), they should immediately seek their physician's advice concerning the continued use of the present multidose container.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection13"></a><a name="section-15.5"></a><p></p>
<h2>
17.5	Concomitant Topical Ocular Therapy</h2>
<p class="First">If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection14"></a><a name="section-15.6"></a><p></p>
<h2>
17.6	Contact Lens Wear</h2>
<p class="First">The preservative in AZOPT® (brinzolamide ophthalmic suspension) 1%, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation of AZOPT® (brinzolamide ophthalmic suspension) 1%, but may be reinserted 15 minutes after instillation.</p>
<p>©2000-2009, 2011-2012 Novartis<br><br><span class="Bold">Rx Only<br></span><span class="Bold"><br></span>U.S. Patent Nos: 5,461,081; 6,071,904.<br>*TRUSOPT is a registered trademark of Merck &amp; Co., Inc.<br><br><span class="Bold">ALCON LABORATORIES, INC.<br></span>Fort Worth, Texas 76134 USA<br>1-800-757-9195<br>MedInfo@AlconLabs.com<br><br><span class="Bold">9007825-0212</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-16"></a><p></p>
<h1>
PRINCIPLE DISPLAY PANEL</h1>
<p class="First">NDA 0065-0275-10</p>
<p>Alcon<span class="Sup">®</span></p>
<p>Azopt<span class="Sup">®</span></p>
<p>(brinzolamide ophthalmic suspension) 1%</p>
<p>10 mL Sterile</p>
<div class="Figure"><img alt="carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e9ea2ae7-1b98-4034-9fba-8ce2225e0145&amp;name=carton.jpg"></div>
<div class="Figure"><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e9ea2ae7-1b98-4034-9fba-8ce2225e0145&amp;name=label.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AZOPT  		
					</strong><br><span class="contentTableReg">brinzolamide suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0065-0275</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BRINZOLAMIDE</strong> (BRINZOLAMIDE) </td>
<td class="formItem">BRINZOLAMIDE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TYLOXAPOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOMER HOMOPOLYMER TYPE C</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0065-0275-10</td>
<td class="formItem">10 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0065-0275-15</td>
<td class="formItem">15 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020816</td>
<td class="formItem">04/30/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alcon Laboratories, Inc.
							(008018525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Alcon Laboratories, Inc. (008018525)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Alcon Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">008018525</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fba05aa8-ae46-a5cf-4487-9dc82eed4f9d</div>
<div>Set id: e9ea2ae7-1b98-4034-9fba-8ce2225e0145</div>
<div>Version: 6</div>
<div>Effective Time: 20120308</div>
</div>
</div> <div class="DistributorName">Alcon Laboratories, Inc.</div></p>
</body></html>
